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Evaluation of urinary N-acetyl-beta-
D-glucosaminidase as a marker 
of early renal damage in patients 
with type 2 diabetes mellitus
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ABSTRACT 
Objective: To evaluate the clinical usefulness of urinary N-acetyl-beta-D-glucosaminidase 
(NAG) excretion for the detection of early tubular damage in type 2 diabetes mellitus (T2DM). 
Subjects and methods: Thirty six patients with T2DM were divided into two groups based on 
urinary albumin to creatinine ratio (ACR): normoalbuminuria (ACR < 30 mg/g; n = 19) and mi-
croalbuminuria (ACR = 30-300 mg/g; n = 17). The following parameters were determined in both 
groups: urinary NAG and albumin, serum and urine creatinine, fasting plasma glucose and gly-
cated hemoglobin (HbA1c). Results: Urinary NAG levels [Units/g creatinine; median (range)] were 
significantly increased in microalbuminuria group [17.0 (5.9 - 23.3)] compared to normoalbumin-
uria group [4.4 (1.5 - 9.2)] (P < 0.001). No differences between groups were observed in fasting 
glucose, HbA1c, serum creatinine levels and estimated glomerular filtration rates (eGFR). Urinary 
NAG positively correlated with ACR (r = 0.628; p < 0.0001), while no significant association was 
observed between NAG and glycemia, HbA1c, serum creatinine and eGFR. Conclusions: The in-
crease of urinary NAG at the microalbuminuria stage of diabetic nephropathy (DN) suggests that 
tubular dysfunction is already present in this period. The significant positive association between 
urinary NAG excretion and ACR indicates the possible clinical application of urinary NAG as a 
complementary marker for early detection of DN in T2DM. Arq Bras Endocrinol Metab. 2014;58(8):798-801
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RESUMO
Objetivo: Avaliar a utilidade clínica da excreção urinária da N-acetil-beta-D-glucosaminidase 
(NAG) para a detecção de dano tubular precoce no diabetes melito tipo 2 (DM2). Sujeitos e méto-
dos: Foram estudados trinta e seis pacientes com DM2 que se dividiram em dois grupos com base 
na excreção urinária de albumina (EUA): normoalbuminúrico (EUA < 30 mg/g de creatinina; n = 19) 
e microalbuminúrico (EUA = 30-300 mg/g de creatinina; n = 17). Em ambos os grupos foram deter-
minados os seguintes parâmetros: NAG e albumina urinária, creatinina sérica e urinária, glicemia 
de jejum e hemoglobina glicada (HbA1c). Resultados: Os níveis de NAG urinária [unidades/g de 
creatinina; mediana (intervalo interquartílico)] foram significativamente maiores no grupo micro-
albuminúrico [17,0 (5,9 - 23,3)] em comparação com o grupo normoalbuminúrico [4,4 (1,5 - 9,2)] 
(p < 0,001). Não se observaram diferenças significativas entre os dois grupos nos níveis de gli-
cemia de jejum, HbA1c, creatinina sérica e taxa de filtração glomerular estimada (TFGe). A NAG 
urinária se correlacionou positivamente com o EUA (r = 0,628, p < 0,0001), não sendo observada 
associação significativa da NAG com glicemia, HbA1c, creatinina sérica e TFGe. Conclusões: O 
aumento da NAG urinária na fase de microalbuminúria da nefropatia diabética (ND) sugere que 
a disfunção tubular já está presente nesse período. A associação positiva significativa entre a ex-
creção urinária da NAG e EUA indica a possível aplicação clínica da NAG urinária como marcador 
complementar para a detecção precoce da ND no DM2. Arq Bras Endocrinol Metab. 2014;58(8):798-801
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INTRODUCTION
D iabetic nephropathy (DN) is a major microvascu-lar complication of diabetes mellitus (DM) beco-
ming the main cause of end-stage renal disease world-
wide. It is assumed that a urinary albumin excretion 
within the range of microalbuminuria constitutes the 
first clinical evidence of DN and is the most impor-
tant non-invasive marker of glomerular alteration and 
disease progression risk. Indeed, in diabetic patients, 
microalbuminuria commonly precedes both clinical al-
buminuria and the decline of renal function (1). On the 
other hand, tubular injury may also be involved in the 
pathogenesis and progression of DN. A wide variety of 
causes related with the pathophysiological alterations 
that develop in the setting of diabetes are contributing 
factors. Examples are hyperglycemia, alterations in va-
soactive hormones, formation of glycation advanced 
end products, hemodynamic changes, protein kinase C 
activation, increased oxidative stress and polyol produc-
tion (2). Furthermore, persistent albuminuria secon-
dary to glomerular lesions may be directly harmful to 
renal tubular cells, leading to tubular inflammation and 
tubulointerstitial fibrosis (3,4). One widely used tubu-
lar injury marker is N-acetyl-beta-D-glucosaminidase 
(NAG) whose presence in the urine invariably signifies 
tubular damage since, due to its high molecular wei-
ght, it is not able to filter by the glomerulus, but it is 
released in the tubular lumen as a consequence of pro-
ximal tubular damage (5). Studies aimed at evaluating 
the utilization of urinary NAG as a marker of tubular 
dysfunction in type 2 DM (T2DM) have not been con-
clusive. While some authors demonstrated that urinary 
NAG is elevated in type 2 diabetic patients with normo-
albuminuria compared to non-diabetic controls (6-8), 
as well as in type 2 diabetic patients with microalbumi-
nuria compared to those with normoalbuminuria (8-
10), others disagree with these findings (11). 
The aim of this study was to evaluate the clinical 
utility of urinary NAG excretion for the detection of 
early tubular dysfunction, particularly referred to the 
possible degree of association with urinary albumin ex-
cretion in type 2 diabetic patients. 
SUBJECTS AND METHODS
We studied 36 patients with T2DM of more than 5 five 
years of evolution who were referred from the Medical 
Clinic Service to the Nephrology Service of the Hospi-
tal Provincial del Centenario of Rosario. The exclusion 
criteria were body mass index (BMI) ≥ 30 kg/m2, his-
tory of other endocrinopathies, hypertension (median 
of blood pressure > 130/80 mmHg determined as trip-
licates, recorded in 2 different opportunities), urinary 
tract infection, renal lithiasis (discarded by kidney ultra-
sonography), proteinuria, abnormal urinary sediment 
(presence of hematuria, pyuria and/or casts) or renal 
failure [estimated glomerular filtration rate (eGFR) 
< 60 mL/min per 1.73 m2] (12). Normoalbuminuria 
was defined as urinary albumin to creatinine ratio (ACR) 
< 30 mg/g and microalbuminuria as ACR = 30-300 
mg/g (12,13). Diabetic patients were categorized into 
two groups based on their ACR: normoalbuminuria 
(n = 19) and microalbuminuria (n = 17). In the normo-
albuminuria group, 5 patients were under diet therapy, 
10 patients received metformin combined with sulfo-
nylureas and 4 patients were in treatment with insulin. 
In the microalbuminuria group, the number of patients 
under diet, metformin combined with sulfonylureas or 
insulin were 3, 8 and 6, respectively. Ethical approval 
was obtained from the Ethics Committee of the Faculty 
of Biochemical and Pharmaceutical Sciences of Rosario.
After 12 hours of overnight fasting, venous blood 
samples were obtained and first morning urine samples 
were collected from each individual. Aliquots of urine 
were then immediately frozen at -80 °C until further 
analysis for no longer than 1 month. Urinary excre-
tion of NAG was measured by colorimetric assay fol-
lowing manufacturer’s instructions (Roche Diagnostics 
GmbH) and results were expressed as Units/g creati-
nine (9). The tests were run in duplicates. Intra-assay 
variation coefficient was < 5%. Urinary concentration 
of albumin was assessed by an immunoturbidimetric 
method (Roche Diagnostics GmbH) and ACR was ex-
pressed as mg/g creatinine (12,13). Microalbuminuria 
was established when two out of three ACR determina-
tions were found to be within the range 30-300 mg/g 
in a six-month period. Creatinine concentration in urine 
and serum was measured by a kinetic method based on 
Jaffe reaction. Serum creatinine values were used to cal-
culate an eGFR, by means of the abbreviated Modifica-
tion of Diet in Renal Disease formula (8,13). Glycemic 
control was evaluated by assessing fasting plasma glu-
cose and glycated hemoglobin (HbA1c). Glucose was 
determined by an enzymatic method in a plasma sample 
obtained with EDTA/fluoride. HbA1c was measured by 
ion-exchange cromatography (Biosystem S. A.) in a 
whole blood sample obtained with EDTA. 
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Normally distributed values were expressed as means 
± SD and compared using the independent-samples 
t test, whereas non-normally distributed values were 
given as median (range) and compared by the Mann-
Whitney U test. After non-normally distributed values 
were log-transformed to better approximate normal 
distributions, correlations were calculated by Pearson’s 
correlation analysis. Categorical data were compared by 
chi-square test. P values of less than 0.05 were consi-
dered statistically significant.
RESULTS
Clinical characteristics of type 2 diabetic patients are 
summarized in table 1. Microalbuminuria group 
showed higher levels of ACR (by design) and urinary 
NAG compared to normoalbuminuria group (P < 
0.001). We found no statistically significant differences 
between both groups in the time of evolution of DM, 
nor in blood pressure, BMI, fasting glucose, HbA1c, se-
rum creatinine levels or eGFR.
Urinary NAG levels were positively correlated with 
ACR levels in all diabetic patients (r = 0.628; P < 0.0001) 
(Figure 1), while no correlation was found between uri-
nary NAG and age, blood pressure, BMI, parameters of 
glycemic control, serum creatinine and eGFR (Table 2). 
Table 1. Clinical characteristics of patients with type 2 diabetes mellitus
Normoalbuminuria Microalbuminuria
n 19 17
Age (years) 68 ± 8 64 ± 13
Gender (M/F) 13/6 8/9
Duration of diabetes (years) 13 ± 8 14 ± 7
Systolic blood pressure (mmHg) 115.0 (110.0 - 120.0) 120.0 (112.5 - 122.0)
Diastolic blood pressure (mmHg) 78.0 (75.0 - 80.0) 80.0 (75.0 - 80.0)
BMI (kg/m2) 27.5 ± 0.2 26.9 ± 0.2
Fasting plasma glucose (mg/dL) 165 ± 33 161 ± 47
HbA
1c
 (%) 10.1 ± 2.0 9.6 ± 1.9
Serum creatinine (mg/dL) 0.90 ± 0.08 0.93 ± 0.16
eGFR Modification of Diet in Renal
Disease (mL/min/1.73 m2)
81 ± 13 74 ± 11 
ACR (mg/g creatinine) 14.0 (10.0 - 18.0) 69.0 (48.0 - 84.5)
Urinary NAG (Units/g creatinine) 4.4 (1.5 - 9.2) 17.0 (5.9 - 23.3)a
Data are presented as means ± SD or median (range). BMI: body mass index. HbA
1c
: glycated 
hemoglobin. eGFR: estimated glomerular filtration rate. ACR: urinary albumin to creatinine ratio. 
NAG: N-acetyl-beta-D-glucosaminidase. Normoalbuminuria: ACR < 30 mg/g creatinine; 
Microabuminuria: ACR = 30-300 mg/g creatinine. P values of microalbuminuria vs. 
normoalbuminuria groups were calculated using the independent-samples t test for normal 
distributed variables and the Mann-Whitney U test for non-normal distributed variables. 
a P < 0.001 vs. normoalbuminuria.
Figure 1. Correlation between urinary N-acetyl-beta-D-glucosaminidase 
(NAG) and urinary albumin levels in type 2 diabetic patients (n = 36). 
Logarithm-transformed urinary NAG levels positively correlate with 
logarithm-transformed urinary albumin to creatinine ratio (ACR) levels (r = 
0.628; P < 0.0001).
Table 2. Correlation (Pearson coefficients) of urinary NAG with age, blood 
pressure, BMI, glycemic control parameters, serum creatinine and eGFR 
in patients with type 2 diabetes mellitus
Variable
NAG
r P
Age -0.259 0.160
Systolic blood pressure 0.134 0.436
Diastolic blood pressure 0.144 0.403
BMI -0.217 0.203
Fasting glycemia -0.201 0.239
HbA
1c
-0.277 0.102
Serum creatinine -0.122 0.480
eGFR -0.0622 0.719
BMI: body mass index. HbA
1c
: glycated hemoglobin. eGFR: estimated glomerular filtration rate. 
DISCUSSION
Although glomerular injury has classically been conside-
red as the cause of early DN, studies in the last two de-
cades have focused on the role of a concomitant or per-
haps earlier occurrence of tubular injury in DN (2,3). 
In the present study we measured urinary NAG excre-
tion, as a marker of tubular damage, in type 2 diabetic 
patients with normo- and microalbuminuria. We found 
that urinary NAG levels were significantly increased 
in patients with microalbuminuria compared to those 
with normoalbuminuria, thus corroborating previous 
studies performed in type 2 diabetic patients (8-10). 
We also observed a significant positive correlation be-
tween urinary NAG excretion and ACR which is consis-
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tent with the data reported by other studies in patients 
with T2DM (14) as well as in type 1 diabetic patients 
(15). These findings suggest that tubular dysfunction, 
evidenced by an increase in urinary NAG excretion, is 
already present in the microalbuminuria stage of DN in 
T2DM and that it becomes exacerbated with the degree 
of albuminuria. The association between the regression 
of microalbuminuria and the decrease in urinary NAG 
observed by Vaidya and cols. (16) in a prospective anal-
ysis performed in type 1 diabetic patients would support 
our hypothesis. 
The lack of correlation between urinary NAG ex-
cretion and glycemic state are consistent with those 
results reported by other authors in type 2 diabetic 
patients (9,14). However, data from the literature re-
ferred to T2DM are controversial (10,17), while in 
type 1 diabetic patients such a relation is more clearly 
evidenced (15).
Despite the relatively small size of the sample and the 
cross sectional design of this study, we are able to state 
that urinary NAG levels are elevated in type 2 diabetic 
patients with microalbuminuria and that these levels cor-
relate with ACR. These findings would suggest a possible 
clinical application of urinary NAG as a complementary 
marker for the detection of early renal disease in T2DM. 
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